NFX vs. EVG, MTFB, GENF, DEST, BSFA, ROQ, RENE, VAL, SALV, and ONC
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Evgen Pharma (EVG), Motif Bio (MTFB), Genflow Biosciences (GENF), Destiny Pharma (DEST), BSF Enterprise (BSFA), Roquefort Therapeutics (ROQ), ReNeuron Group (RENE), ValiRx (VAL), SalvaRx Group (SALV), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.
Nuformix vs. Its Competitors
Nuformix (LON:NFX) and Evgen Pharma (LON:EVG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
In the previous week, Nuformix's average media sentiment score of 0.00 equaled Evgen Pharma'saverage media sentiment score.
Nuformix currently has a consensus price target of GBX 293, suggesting a potential upside of 281,630.77%. Given Nuformix's stronger consensus rating and higher probable upside, research analysts clearly believe Nuformix is more favorable than Evgen Pharma.
Nuformix has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Evgen Pharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.
Nuformix's return on equity of -5.68% beat Evgen Pharma's return on equity.
Nuformix is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.
0.1% of Nuformix shares are held by institutional investors. Comparatively, 27.8% of Evgen Pharma shares are held by institutional investors. 12.4% of Nuformix shares are held by company insiders. Comparatively, 32.4% of Evgen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Evgen Pharma received 124 more outperform votes than Nuformix when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 66.99% of users gave Nuformix an outperform vote.
Summary
Nuformix beats Evgen Pharma on 7 of the 13 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 6/15/2025 by MarketBeat.com Staff
